Disclosed herein are
ruthenium arene Schiff-base complex and uses thereof. The
ruthenium arene Schiff-base complex disclosed herein has the structure of formula (I),wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are independently H,
alkyl, alkoxyl, or halo; R13, R14, R15, R16, and R17 are independently H,
alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH2, —SO3H, —SO2NH2, —NR′R″, or —CONH2; or R13 and R14 are taken together to form a
benzene ring, while R15, R16, and R17 are independently H,
alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH2, —SO3H, —SO2NH2, —NR′R″, or —CONH2; or R14 and R15 are taken together to form a
benzene ring, while R13, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH2, —SO3H, —SO2NH2, —NR′R″, or —CONH2; R′ and R″ are independently H or alkyl; the alkyl is optionally substituted with one or more halo or hydroxy, or hydroxy; and Y is a counter anion. Also disclosed herein are methods of treating malignant
neoplasm in a subject. The method includes administering an effective amount of the
ruthenium arene Schiff-base complex of formula (I) to the subject to alleviate symptoms associated with the malignant
neoplasm. Exemplary malignant
neoplasm includes, but is not limited to triple-negative
breast cancer.